Agilent Technologies Inc. announced that it has signed a definitive agreement to acquire privately-held Advanced Analytical Technologies, Inc. (AATI), a provider of capillary electrophoresis-based (CE) solutions for fully-automated analysis of a range of molecules for $250 million in cash. ... more
Agilent Technologies Secures Patent for CGH Assays
Agilent Technologies Inc. announced that it was awarded a significant patent for comparative genomic hybridization methods. CGH methods help researchers study genetics and cancer in both basic and clinical research.
The U.S. patent (No. 8,232,055) has claims for measuring copy number changes in genomic DNA, covering both one-color and two-color assays using oligonucleotide probes and samples with high-sequence complexity, such as human genomic DNA samples.
Agilent’s copy number method, commercially introduced in 2005, uses long oligonucleotide probes, enabling high specificity and sensitivity. For example, samples containing as low as 8 percent abnormal cells may be confidently analyzed with Agilent’s copy number method.
The method was originally developed to improve upon older copy number assays that use long genomic fragments such as bacterial artificial chromosomes. (BACs often contain repetitive regions.) The method also improves upon other oligonucleotide array assays, which depend on sample preparation methods that remove significant portions of the genomic DNA content. Agilent’s higher-resolution platform allows users to detect much smaller genomic aberrations throughout complex genomes.
- Agilent Technologies
- comparative genomic…
- oligonucleotide probes
Agilent Technologies Inc. announced it has acquired Oxfordshire, U.K.-based Cobalt Light Systems, a provider of highly differentiated Raman spectroscopic instruments for the pharmaceutical industry, applied markets and public safety. Cobalt’s innovative suite of benchtop and handheld/porta ... more
Agilent Technologies Inc. and Agendia, Inc. today jointly announced an agreement to expand their relationship to include the development of an RNASeq kit version of Agendia’s currently marketed MammaPrint and BluePrint tests. Agendia’s MammaPrint test provides High-Risk or Low-Risk test re ... more